Chronic inflammatory demyelinating polyneuropathy
ORPHA:2932DiseaseNot applicableAdolescent, Adult, Childhood, Elderly
Фенотипы (HPO)21
Очень частый (80–99%)12
HP:0000762Decreased nerve conduction velocity
HP:0001284Areflexia
HP:0002317Unsteady gait
HP:0003401Paresthesia
HP:0003474Somatic sensory dysfunction
HP:0003481Segmental peripheral demyelination/remyelination
HP:0009830Peripheral neuropathy
HP:0010871Sensory ataxia
HP:0011096Peripheral demyelination
HP:0012078Motor conduction block
HP:0030200Fatiguable weakness of proximal limb muscles
HP:0040129Abnormal nerve conduction velocity
Частый (30–79%)8
HP:0002527Falls
HP:0003551Difficulty climbing stairs
HP:0030237Hand muscle weakness
HP:0034135Anti-neurofascin-155 antibody positivity
HP:0034136Anti-neurofascin 186 antibody positivity
HP:0034137Anti-contactin-1 antibody positivity
HP:0034138Anti-contactin-associated protein 1 antibody positivity
HP:0001288Gait disturbance
Периодический (5–29%)1
HP:0010833Spontaneous pain sensation
Эпидемиология10
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Point prevalence | 1-9 / 100 000 | 3.7 | Europe | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.36 | Italy | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.6 | United Kingdom | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.86 | Italy | Value and class |
| Point prevalence | 1-9 / 100 000 | 7.7 | Norway | Value and class |
| Point prevalence | 1-5 / 10 000 | 12 | Egypt | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.48 | Japan | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.61 | Japan | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.15 | Australia | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.9 | Australia | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)